At the immune level, it recruits myeloid-derived suppressor cells (MDSCs) to tumor regions, inhibiting CD8+ T cell cytotoxic activity, forming synergistic “vascular protection-immune evasion” effects, further consolidating scPAS + cell survival advantages. This evidence concerns the gene CD8A and neoplasm.